<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058291</url>
  </required_header>
  <id_info>
    <org_study_id>6500-004</org_study_id>
    <nct_id>NCT01058291</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500</brief_title>
  <acronym>6500-004</acronym>
  <official_title>Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a placebo-controlled double-blind crossover comparative study of KW-6500 in&#xD;
      Parkinson's disease patients with motor response complications on levodopa therapy. The&#xD;
      efficacy of KW-6500 is evaluated using the change of UPDRS part III score at double blind&#xD;
      period after 12 weeks subcutaneous self-injections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The raw score change in UPDRS part III score</measure>
    <time_frame>At the double blind period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent score change in UPDRS part III score and response ratio</measure>
    <time_frame>At the double blind period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>KW-6500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KW-6500 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6500</intervention_name>
    <description>Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state</description>
    <arm_group_label>KW-6500</arm_group_label>
    <other_name>Apomorphine hydroshloride (USAN)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6500 Placebo</intervention_name>
    <description>Twelve weeks subcutaneous injection for the OFF state</description>
    <arm_group_label>KW-6500 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have given written informed consent&#xD;
&#xD;
          -  Patients who have Parkinson's disease&#xD;
&#xD;
          -  Patients who have been on a stable regimen of levodopa plus at least one other&#xD;
             antiparkinsonian agent and who have OFF state&#xD;
&#xD;
          -  Patients who meet stage 4 or 5 while in the OFF state and stage 0 to 3 while in the ON&#xD;
             state on the Modified Hoehn and Yahr Scale&#xD;
&#xD;
          -  Patients who have experienced a 30% or more improvement in Unified Parkinson's Disease&#xD;
             Rating Scale (UPDRS) partâ…¢ score when tested for responsiveness to levodopa during the&#xD;
             baseline period&#xD;
&#xD;
          -  Patients who have at least one OFF state per day&#xD;
&#xD;
          -  Patients who can understand the expression of OFF state, ON state, and dyskinesia&#xD;
&#xD;
          -  Patients or their families have a desire for self-injection of KW-6500&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic,&#xD;
             metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system&#xD;
             (excluding Parkinson's disease)&#xD;
&#xD;
          -  Patients with orthostatic hypotension&#xD;
&#xD;
          -  Patients with a history of intolerance to morphine or its derivatives, sulfur,&#xD;
             sulfur-containing pharmaceutical products, or sulfite&#xD;
&#xD;
          -  Patients with a history of malignant syndrome&#xD;
&#xD;
          -  Patients with a diagnosis of cancer or evidence of continued disease&#xD;
&#xD;
          -  Patients who do not test negative in the direct Coombs' test&#xD;
&#xD;
          -  Pregnant or lactating women, women who are planning to have children, women who test&#xD;
             positive in the pregnancy test, or women who cannot adhere to a reliable method of&#xD;
             contraception&#xD;
&#xD;
          -  Patients who have received MAO inhibitors except selegiline&#xD;
&#xD;
          -  Patients with a history of mental disease (excluding psychiatric symptoms associated&#xD;
             with Parkinson's disease)&#xD;
&#xD;
          -  Patients with a Mini-Mental State Examination score of 23 or less&#xD;
&#xD;
          -  Patients who are taking antipsychotics or central dopamine antagonists (excluding&#xD;
             domperidone)&#xD;
&#xD;
          -  Patients who are receiving methyldopa or 5-HT3 receptor antagonists&#xD;
&#xD;
          -  Patients who are receiving reserpine or papaverine&#xD;
&#xD;
          -  Patients who have had a neurosurgical operation for Parkinson's disease&#xD;
&#xD;
          -  Patients who have had transcranial magnetic stimulation&#xD;
&#xD;
          -  Patients with a history of drug or alcohol abuse or dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

